Literature DB >> 28550246

Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.

Kacie D Deters1,2,3, Shannon L Risacher1,2, Sungeun Kim1,2,4, Kwangsik Nho1,2, John D West1, Kaj Blennow5, Henrik Zetterberg5,6, Leslie M Shaw7, John Q Trojanowski7, Michael W Weiner8, Andrew J Saykin1,2,3.   

Abstract

BACKGROUND: Peripheral (plasma) and central (cerebrospinal fluid, CSF) measures of tau are higher in Alzheimer's disease (AD) relative to prodromal stages and controls. While elevated CSF tau concentrations have been shown to be associated with lower grey matter density (GMD) in AD-specific regions, this correlation has yet to be examined for plasma in a large study.
OBJECTIVE: Determine the neuroanatomical correlates of plasma tau using voxel-based analysis.
METHODS: Cross-sectional data for 508 ADNI participants were collected for clinical, plasma total-tau (t-tau), CSF amyloid (Aβ42) and tau, and MRI variables. The relationship between plasma tau and GMD and between CSF t-tau and GMD were assessed on a voxel-by-voxel basis using regression models. Age, sex, APOEɛ4 status, diagnosis, and total intracranial volume were used as covariates where appropriate. Participants were defined as amyloid positive (Aβ+) if CSF Aβ42 was <192 pg/mL.
RESULTS: Plasma tau was negatively correlated with GMD in the medial temporal lobe (MTL), precuneus, thalamus, and striatum. The associations with thalamus and striatum were independent of diagnosis. A negative correlation also existed between plasma tau and GMD in Aβ+ participants in the MTL, precuneus, and frontal lobe. When compared to CSF t-tau, plasma tau showed a notably different associated brain atrophy pattern, with only small overlapping regions in the fusiform gyrus.
CONCLUSION: Plasma tau may serve as a non-specific marker for neurodegeneration but is still relevant to AD considering low GMD was associated with plasma tau in Aβ+ participants and not Aβ-participants.

Entities:  

Keywords:  Alzheimer disease; magnetic resonance imaging; mild cognitive impairment; plasma; tau protein

Mesh:

Substances:

Year:  2017        PMID: 28550246      PMCID: PMC5523909          DOI: 10.3233/JAD-161114

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  17 in total

1.  Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system.

Authors:  B Fischl; M I Sereno; A M Dale
Journal:  Neuroimage       Date:  1999-02       Impact factor: 6.556

2.  Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study.

Authors:  Jeffrey Randall; Erik Mörtberg; Gail K Provuncher; David R Fournier; David C Duffy; Sten Rubertsson; Kaj Blennow; Henrik Zetterberg; David H Wilson
Journal:  Resuscitation       Date:  2012-08-09       Impact factor: 5.262

Review 3.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

4.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 5.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Bob Olsson; Ronald Lautner; Ulf Andreasson; Annika Öhrfelt; Erik Portelius; Maria Bjerke; Mikko Hölttä; Christoffer Rosén; Caroline Olsson; Gabrielle Strobel; Elizabeth Wu; Kelly Dakin; Max Petzold; Kaj Blennow; Henrik Zetterberg
Journal:  Lancet Neurol       Date:  2016-04-08       Impact factor: 44.182

6.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

7.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.

Authors:  Matthew R Brier; Brian Gordon; Karl Friedrichsen; John McCarthy; Ari Stern; Jon Christensen; Christopher Owen; Patricia Aldea; Yi Su; Jason Hassenstab; Nigel J Cairns; David M Holtzman; Anne M Fagan; John C Morris; Tammie L S Benzinger; Beau M Ances
Journal:  Sci Transl Med       Date:  2016-05-11       Impact factor: 17.956

8.  The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI).

Authors:  Shannon L Risacher; Sungeun Kim; Li Shen; Kwangsik Nho; Tatiana Foroud; Robert C Green; Ronald C Petersen; Clifford R Jack; Paul S Aisen; Robert A Koeppe; William J Jagust; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Andrew J Saykin
Journal:  Front Aging Neurosci       Date:  2013-04-01       Impact factor: 5.750

9.  Plasma tau levels in Alzheimer's disease.

Authors:  Henrik Zetterberg; David Wilson; Ulf Andreasson; Lennart Minthon; Kaj Blennow; Jeffrey Randall; Oskar Hansson
Journal:  Alzheimers Res Ther       Date:  2013-03-28       Impact factor: 6.982

10.  Plasma tau in Alzheimer disease.

Authors:  Niklas Mattsson; Henrik Zetterberg; Shorena Janelidze; Philip S Insel; Ulf Andreasson; Erik Stomrud; Sebastian Palmqvist; David Baker; Cristina A Tan Hehir; Andreas Jeromin; David Hanlon; Linan Song; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Oskar Hansson; Kaj Blennow
Journal:  Neurology       Date:  2016-09-30       Impact factor: 9.910

View more
  27 in total

1.  Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes.

Authors:  Matthew P Pase; Alexa S Beiser; Jayandra J Himali; Claudia L Satizabal; Hugo J Aparicio; Charles DeCarli; Geneviève Chêne; Carole Dufouil; Sudha Seshadri
Journal:  JAMA Neurol       Date:  2019-05-01       Impact factor: 18.302

2.  Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease.

Authors:  Zhicheng Chen; David Mengel; Ashvini Keshavan; Robert A Rissman; Andrew Billinton; Michael Perkinton; Jennifer Percival-Alwyn; Aaron Schultz; Michael Properzi; Keith Johnson; Dennis J Selkoe; Reisa A Sperling; Purvish Patel; Henrik Zetterberg; Douglas Galasko; Jonathan M Schott; Dominic M Walsh
Journal:  Alzheimers Dement       Date:  2018-11-09       Impact factor: 21.566

Review 3.  Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.

Authors:  Thomas K Karikari; Nicholas J Ashton; Gunnar Brinkmalm; Wagner S Brum; Andréa L Benedet; Laia Montoliu-Gaya; Juan Lantero-Rodriguez; Tharick Ali Pascoal; Marc Suárez-Calvet; Pedro Rosa-Neto; Kaj Blennow; Henrik Zetterberg
Journal:  Nat Rev Neurol       Date:  2022-05-18       Impact factor: 44.711

4.  Data-Driven Analyses of Longitudinal Hippocampal Imaging Trajectories: Discrimination and Biomarker Prediction of Change Classes.

Authors:  Shannon M Drouin; G Peggy McFall; Olivier Potvin; Pierre Bellec; Mario Masellis; Simon Duchesne; Roger A Dixon
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

5.  Investigation of Underlying Association Between Whole Brain Regions and Alzheimer's Disease: A Research Based on an Artificial Intelligence Model.

Authors:  Shui Liu; Chen Jie; Weimin Zheng; Jingjing Cui; Zhiqun Wang
Journal:  Front Aging Neurosci       Date:  2022-06-07       Impact factor: 5.702

6.  Cerebrospinal fluid tau, Aβ, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration.

Authors:  Michael L Alosco; Yorghos Tripodis; Nathan G Fritts; Amanda Heslegrave; Christine M Baugh; Shannon Conneely; Megan Mariani; Brett M Martin; Samuel Frank; Jesse Mez; Thor D Stein; Robert C Cantu; Ann C McKee; Leslie M Shaw; John Q Trojanowski; Kaj Blennow; Henrik Zetterberg; Robert A Stern
Journal:  Alzheimers Dement       Date:  2018-07-23       Impact factor: 21.566

7.  Hearing loss and dementia: radiologic and biomolecular basis of their shared characteristics. A systematic review.

Authors:  Arianna Di Stadio; Massimo Ralli; Dalila Roccamatisi; Alfonso Scarpa; Antonio Della Volpe; Claudia Cassandro; Giampietro Ricci; Antonio Greco; Evanthia Bernitsas
Journal:  Neurol Sci       Date:  2021-01-07       Impact factor: 3.307

8.  Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.

Authors:  Inge M W Verberk; Rosalinde E Slot; Sander C J Verfaillie; Hans Heijst; Niels D Prins; Bart N M van Berckel; Philip Scheltens; Charlotte E Teunissen; Wiesje M van der Flier
Journal:  Ann Neurol       Date:  2018-10-04       Impact factor: 10.422

9.  Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
.

Authors:  Harald Hampel; Andrea Vergallo; Mohammad Afshar; Leyla Akman-Anderson; Joaquín Arenas; Norbert Benda; Richard Batrla; Karl Broich; Filippo Caraci; A Claudio Cuello; Enzo Emanuele; Marion Haberkamp; Steven J Kiddle; Alejandro Lucía; Mark Mapstone; Steven R Verdooner; Janet Woodcock; Simone Lista
Journal:  Dialogues Clin Neurosci       Date:  2019       Impact factor: 5.986

Review 10.  Current state of Alzheimer's fluid biomarkers.

Authors:  José Luis Molinuevo; Scott Ayton; Richard Batrla; Martin M Bednar; Tobias Bittner; Jeffrey Cummings; Anne M Fagan; Harald Hampel; Michelle M Mielke; Alvydas Mikulskis; Sid O'Bryant; Philip Scheltens; Jeffrey Sevigny; Leslie M Shaw; Holly D Soares; Gary Tong; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow
Journal:  Acta Neuropathol       Date:  2018-11-28       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.